Generics help offset steep price hikes on brand-name drugs | Durbin asks Democrats to discuss Medicare, Medicaid reforms | Expert: Proposed EHB rule offers formulary flexibility
November 28, 2012
PCMA SmartBrief
News for the PBM Industry

Featured Story
Generics help offset steep price hikes on brand-name drugs
Prices for brand-name drugs in the U.S. rose 13.3% from September 2011 to September 2012, and spending on specialty drugs has climbed 22.6% over the first three quarters of 2011, according to a study by pharmacy benefit manager Express Scripts. However, a generic drug utilization rate close to 80% helped curb overall drug spending, the study found. Reuters (11/28)
Share: LinkedInTwitterFacebookGoogle+Email
Registration is now open for PCMA's Managed Markets Educational Forum!
Whether you are a seasoned managed markets executive or someone who supports the team, PCMA's Managed Markets Educational Forum will provide valuable education on fundamental, as well as complex and strategic issues relevant to professionals of all levels within pharma managed markets or market access divisions. Visit PCMA's website to learn more about our 2013 events!
Legislative & Regulatory News
Durbin asks Democrats to discuss Medicare, Medicaid reforms
Democrats should consider how to reform Medicaid and Medicare to ensure the programs' "long-term viability," Sen. Dick Durbin, D-Ill, told the Center for American Progress. Reuters (11/27)
Share: LinkedInTwitterFacebookGoogle+Email
PBM Industry News
Expert: Proposed EHB rule offers formulary flexibility
Proposed HHS rules would require that insurance plans sold on exchanges cover the greater of either one drug in each therapeutic class or the same number of drugs in each class as covered in a state's benchmark plan. The requirement applies to the number of drugs covered, leaving open the option of including different drugs on plan formularies, writes industry expert Adam Fein. Drug Channels (11/27)
Share: LinkedInTwitterFacebookGoogle+Email
Drug Industry Spotlight
FTC files amicus brief supporting Mylan
The Federal Trade Commission filed a friend-of-the-court brief in support of Mylan's assertion that Warner Chilcott made minor changes to acne drug Doyrx in an effort to thwart generic competition. Pharmalot/Pharma blog (11/28)
Share: LinkedInTwitterFacebookGoogle+Email
Indian patent board upholds ruling against AstraZeneca
India's Intellectual Property Appellate Board dismissed AstraZeneca's challenge to a ruling that negated the drugmaker's patent on a quinazoline derivative. The ruling is similar to other recent rulings in the country voiding drugmaker patents. Reuters (11/28)
Share: LinkedInTwitterFacebookGoogle+Email
Wockhardt gets 3 generic-drug approvals from FDA
The FDA has granted Wockhardt approval for its generic version of Bristol-Myers Squibb and Sanofi's anticoagulant Plavix. The company has also received approvals for its generic copies of GlaxoSmithKline's antidepressant drug Wellbutrin SR and Novartis' Parkinson's disease drug Stalevo. Drug Store News (11/27)
Share: LinkedInTwitterFacebookGoogle+Email
Teva holds off on launch of generic HIV drugs
Teva will wait until June to launch generic versions of Gilead's Truvada and Viread unless a judge rules before then in Teva's favor in a patent infringement case. Bloomberg (11/27)
Share: LinkedInTwitterFacebookGoogle+Email
The foolish man seeks happiness in the distance; the wise grows it under his feet."
-- James Oppenheim,
American poet, novelist and editor
Share: LinkedInTwitterFacebookGoogle+Email
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 216 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
(202) 207-3610
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tom Parks

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information